Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms
VEGF-targeted therapy is currently the first line treatment for patients with metastatic clear cell renal cell carcinoma (ccRCC), but most patients either display primary (intrinsic) resistance or acquire drug resistance. In recent years multiple mechanisms of resistance to VEGF-targeted therapy emerged from preclinical research, but it is currently unknown to what extent these drug resistance modalities play a role in the clinic. Here we reviewed the current literature on biomarkers that predict treatment outcome in patients with ccRCC to gain insight in clinical drug resistance mechanisms.
Source: Drug Resistance Updates - Category: Drugs & Pharmacology Authors: Johannes C. van der Mijn, James W. Mier, H.J. Broxterman, Henk M. Verheul Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Kidney Cancer | Renal Cell Carcinoma